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Background: The aim of this study was to investigate the effects of surgical castration, particularly
delaying the time to entrance of systemic chemotherapy, in castration-resistant prostate cancer (CRPC)
patients who were refractory to initial combination androgen deprivation therapy.
Materials and methods: We analyzed the clinical data of 14 CRPC patients diagnosed at Seoul National
University Bundang Hospital (SNUBH) from November 2008 through May 2015. After exclusion of three
patients, we ﬁnally analyzed the baseline characteristics of 11 CRPC patients. We also assessed the
delaying time of docetaxel administration, which was deﬁned as response duration, after surgical
castration.
Results: After bilateral orchiectomy, the treatment response rate was 45.4% and the median duration of
response was 9 months (range 4e48 mo). Responders had less aggressive biopsy Gleason scores
compared to nonresponders. Notably, responders showed the reducing pattern of serum prostate speciﬁc
antigen levels, while nonresponders demonstrated increasing tendency after surgical castration. More-
over, responders also presented with a reduction pattern of serum testosterone levels, whereas non-
responders showed an increasing pattern of testosterone levels after bilateral orchiectomy.
Conclusions: In summary, despite the limited number of cases for convincing evidence, our results shed
light again on the clinical beneﬁts of surgical castration prior to the systemic chemotherapy in some
CRPC patients after initial hormone therapy.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Castration-resistant prostate cancer (CRPC) is a clinically sig-
niﬁcant disease due to its aggressiveness and lack of curative
treatment modalities.1 Prior to development of CRPC, patients are
initially treated with androgen deprivation therapy (ADT) such as
luteinizing hormone-releasing hormone (LHRH) agonists and anti-
androgen agents.2 In CRPC various therapeutic agents can be
adopted, including androgen receptor targeted drugs, taxane
chemotherapy and immunotherapy.3 Among these, taxane-based
chemotherapy such as docetaxel is regarded as a ﬁnal treatment
option for CRPC patients with improvement of survival, Seoul National University
-gu, Seongnam, Gyeonggi-do,
ciﬁc Prostate Society, Published boutcomes.4,5 However, survival gain of taxane-based chemotherapy
is not substantialdless than 4e5 months6dand therefore; physi-
cians and researchers have struggled to develop new therapeutic
strategy to delay the time of administration of chemotherapy as
much as possible.
According to the contemporary guidelines, CRPC is initially
responsive to second-line hormone therapy, such as ketoconazole
and antiandrogen withdrawal, whereas hormone-refractory pros-
tate cancer is eventually not responsive to any hormone manipu-
lation.1,7e9 In this regard, controlling androgen or testosterone
levels appropriately is an important issue in CRPC patients to
determine further therapeutic strategy.10 Surgical castration
(bilateral orchiectomy) and medical castration (LHRH agonists) are
the mainstays for achieving castrate testosterone levels.11 However,
LHRH agonists cannot induce the complete castration levels of
testosterone in some patients.12 Instead, surgical castration can
completely eliminate remaining testosterone produced by the
Leydig cells in testes.13y Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 3 (2015) 123e126124In this study, we assessed the effects of surgical castration,
particularly delaying the time to entrance of systemic chemo-
therapy, in CRPC patients who were refractory to initial combina-
tion ADT.
2. Material and methods
2.1. Study population
We reviewed the clinical data of 14 CRPC patients diagnosed at
Seoul National University Bundang Hospital (SNUBH) from
November 2008 through May 2015. We deﬁned castration-
resistant prostate cancer if the patients showed disease progres-
sion despite a castrate testosterone level less than 50 ng/dL, pre-
sented with three consecutive rises of serum prostate-speciﬁc
antigen (PSA) above nadir, and if there was radiological/clinical
progression on androgen blockade therapy.14 Among these, 3 pa-
tients were excluded from analysis due to follow-up loss. Thus, we
ﬁnally analyzed 11 patients with CRPC who underwent bilateral
orchiectomy. The Institutional Review Board at SNUBH approved
our study.
2.2. Study design
We examined the baseline characteristics of 11 patients with
CRPC as follows: age, initial serum PSA, biopsy Gleason score (GS),
type of ADT, and duration of ADT. We also measured the serum PSA
and testosterone levels before and after bilateral orchiectomy,
serum PSA levels at nadir status, and duration of PSA nadir, by
obtaining blood samples from CRPC patients. We performed the
bilateral subcapsular orchiectomy with epididymal sparing ac-
cording to the standard protocol.15 There were no substantial
complications related to surgery. We ﬁnally assessed the delaying
time of docetaxel administration (or response duration) after sur-
gical castration. We divided patients into two groups (responder
and nonresponder) according to the treatment responses to sur-
gical castration. Treatment response was deﬁned if the delaying
time to docetaxel treatment was more than 3 months. According to
the routine follow-up protocol of our hospital, wemonitored serum
PSA levels every 1e2 months.
3. Results
The clinical characteristics of 11 CRPC patients who underwent
bilateral orchiectomy after combined ADT are summarized in
Table 1. Among these, treatment responses to surgical castration
were found in 5 patients (response rate 45.4%). Of note, in the
responder group with delaying time of docetaxel treatment, theTable 1
Baseline characteristics of men with castration-resistant prostate cancer undergoing bila
Groupa) Age
(y)
Initial PSA
(mg/mL)
Biopsy GS ADT type ADT
duration (mo)
PS
Responders 68 378.0 8 (4 þ 4) G & B 13
66 17.4 8 (4 þ 4) G & B 17
64 16.7 d G & B 24
73 51.0 8 (4 þ 4) G & B 22
70 78.3 9 (4 þ 5) G & B 41
Nonresponders 53 >100 8 (4 þ 4) L & B 13
72 d d G & B 9
65 75.1 10 (5 þ 5) G & B 24
65 32.3 9 (4 þ 5) G & B 24
68 17.0 8 (4 þ 4) G & B 50
78 91.0 10 (5 þ 5) G & B 69
a) Cases are divided into two groups (responder and nonresponder) according to the trea
ADT, androgen deprivation therapy; B, biclutamide; C, cyproterone acetate; DCT, docetaxel;
PSA, prostate-speciﬁc antigen; T, testosterone.median duration of response was 9 months (range 4e48 mo).
Although initial serum PSA levels were variable among patients, the
responder group had less aggressive biopsy GS compared to non-
responders. While most responders had biopsy GS 8(4þ 4) and
only one patient had GS 9(4þ 5), there were two patients of GS
10(5þ 5), one patient of GS 9(4þ 5), and two patients of GS 8(4þ 4)
in the nonresponder group. Median duration of ADT was similar
between responder and nonresponder groups (22 mo vs. 24 mo,
respectively)
Notably, the responsiveness of serum PSA and testosterone
levels after bilateral orchiectomy were different between re-
sponders and nonresponders (Fig. 1). Responders showed the
reducing tendency of serum PSA levels, while nonresponders
demonstrated increasing tendency after surgical castration
(Fig. 1A). Moreover, responders also presented a reduction pattern
of serum testosterone levels, whereas nonresponders showed an
upregulating pattern of testosterone levels after bilateral orchiec-
tomy (Fig. 1B). These results indicate that surgical castration can
offer the clinically beneﬁcial effects, such as delaying the time to
chemotherapy, on CRPC patients who are refractory to initial ADT.
4. Discussion
For treating metastatic prostate cancer, there are four types of
androgen deprivation therapy (ADT), including simple orchid-
ectomy, LHRH agonists, anti-androgens, and gonadotrophin
releasing hormone (GnRH) antagonists.16 Among these, LHRH ag-
onists are primarily regarded as the ﬁrst line therapy of ADT since it
was ﬁrst introduced in the early 1980s.17 In the mechanistic view of
ADT on prostate cancer, optimal testosterone control is the
important issue in patients receiving ADT.18 Although these agents
are an alternative therapeutic modality to surgical castration with
similar overall survival beneﬁts, suboptimal testosterone control is
the critical drawback in a signiﬁcant number of patients.18e23 For
example, Oefelein et al21 reported that 13% of prostate cancer (PCa)
patients treated with LHRH agonists failed to achieve castrate level
of testosterone (20 ng/dL). In the cross-sectional study by Morote
et al,23 approximately 11% of advanced PCa patients managed by
LHRH agonist did not eventually achieve the castrate testosterone
levels. In this regard, some patients who have relapsed disease after
initial treatment with LHRH agonists may signiﬁcantly show the
clinical and biochemical responses to surgical castration. For
example, a recent case report demonstrated that two CRPC patients
whowere resistant to LHRH agonists demonstrated good responses
to bilateral orchiectomy, resulting in decreases of serum PSA and
clinical improvement.24 However, there is still little evidence of the
potential beneﬁts of surgical castration in the patients who are
resistant to medical castration.teral orchiectomy.
A (ng/mL)
at ox
1st PSA (ng/mL)
after ox
T (ng/dL)
at ox
1st T (ng/dL)
after ox
DCT Delaying
time (mo)
103.2 87.3 16 13 Not yet 13
9.1 6.1 17 5 Not yet 6
12.7 12.6 18 12 Not yet 4
8.1 7.7 9 7 Not yet 9
133.2 d d d Not yet 48
28.8 28.2 6 12 Add 1
379.2 578 22 34 Add 0
103.9 195.3 34 15 Add 0
52.6 79.2 11 5 Add 0
14.8 24.5 9 11 Add 1
91.4 81.2 19 75 Add 1
tment responses to surgical castration.
G, goserelin acetate, GS, Gleason score; L, leuprorelin acetate; ox, bilateral orchiectomy;
Fig. 1. Clinical responsiveness of patients with castration-resistant prostate cancer by surgical castration. (A) Serum prostate-speciﬁc antigen (PSA) levels before (nonresponder) and
after (responder) bilateral orchiectomy. (B) Serum testosterone levels before (nonresponder) and after (responder) bilateral orchiectomy. PSA and testosterone values of nonre-
sponder and responder group are represented with blue and orange lines, respectively. Ox, orchiectomy; PSA, prostate-speciﬁc antigen.
Kang et al / Revisiting surgical castration for CRPC patients 125In the present study, one key observation was that the
responder group (approximately 50% of patients) showed the time
delaying of docetaxel treatment with reducing pattern of PSA after
bilateral orchiectomy compared to the nonresponder group. This
means that surgical castration may be effective for controlling
disease status in some CRPC patients who are resistant to initial
ADT. Similar to our ﬁndings, there are potential hypotheses to
explain the beneﬁcial effects of surgical castration in the patients
who are refractory to initial ADT. First, some patients who are
resistant to LHRH-agonists may not achieve the castrate testos-
terone levels after sufﬁcient treatment duration by unknown
mechanisms in the hypothalamoepituitaryegonadal axis.13 Sec-
ond, other patients who are resistant to LHRH-agonists present
with serum testosterone levels decreased to castration levels by
deﬁnition; however, testosterone cannot be diminished low
enough under clinically hormone-refractory states. Therefore,
insufﬁcient reduction of serum testosterone may upregulate the
expression of androgen receptor and its target genes and eventually
stimulate the oncogenic signaling pathways despite the low level of
serum testosterone.25 Third, the residual Leydig cells in hormonal
treatment-induced atrophic testes may act as functional units,
which are responsible for the testosterone resurgence and the
failure of LHRH agonist therapy. Indeed, Leydig cell hyperplasia was
a poor predictive sign for treatment response of LHRH agonists in
the study by Olaopa et al.24 They noted that two patients demon-
strated a substantial response to bilateral orchiectomy for Leydig
cells ablation, while one patient who had small amounts of Leydig
cells showed a poor response to surgical castration.24Another important observation was that the responder popu-
lation presented a reduction pattern of serum testosterone levels
after bilateral orchiectomy, whereas the nonresponder population
demonstrated upregulating tendency even after surgical castration.
Because testosterone levels of both responders and nonresponders
were lower than 20 ng/dL after initial ADT, previously described
hypotheses related to suboptimal castration levels and Leydig cells
hyperplasia cannot explain the results. Instead, Mostaghel et al26
recently suggested that intraprostatic androgens and their target
gene expression can be the potential mechanism of the insufﬁcient
responses of medical ADT despite the castrate serum testosterone
levels. That is, medical castration dependent on serum testosterone
cannot fully represent the androgen status within the prostate
tissue harboring cancer. They hypothesized that suboptimal
reduction of intraprostatic testosterone and resultant activation of
androgen-regulated genes can render prostate cancer cells to adapt
to survive in a low-testosterone microenvironment.26 Gregory
et al27 also suggested that metabolic adaptation of prostate cancer
cells may contribute to the resistance to hormonal treatments, and
thus therapeutic strategy for repressing substantially the tumoral
androgen activity should be required.27 In this context, we believe
that surgical castration can be considered as a potential therapeutic
option prior to docetaxel treatment in metastatic CRPC patients
who are resistant to initial ADT, particularly with castrate serum
testosterone levels. To achieve the optimal clinical efﬁcacy by sur-
gical castration in these patients, novel tools for measuring intra-
prostatic androgen status should be developed to select
appropriate patients.
Prostate Int 3 (2015) 123e126126We should acknowledge several critical limitations in the pre-
sent study. First, our study has a retrospective nature with a small
number of cases. Second, we cannot offer the pathologic data to
represent the status of Leydig cells or intraprostatic androgen with
its target genes at the molecular level. Finally, we cannot clearly
explain the heterogeneity in treatment responses of bilateral or-
chiectomy observed between responders and nonresponders.
Nevertheless, our study highlights the clinical effectiveness of
surgical castration by bilateral orchiectomy in some CRPC patients
who are resistant to initial ADT, and provides the potential mech-
anisms of these phenomena.
In summary, despite the limited number of patients for statis-
tical analysis, our results shed light again on the clinical beneﬁts of
surgical castration by bilateral orchiectomy prior to systemic
chemotherapy in some CRPC patients after initial hormone therapy.
Further histopathological analysis with large case numbers is
required to support our preliminary results.
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